Medicare Launches $50/Month GLP-1 Weight-Loss Drug Trial: What Beneficiaries Need to Know
By
Associated Press
Summary
Starting this week, the federal government launched a new trial program called Medicare GLP-1 Bridge, offering certain GLP-1 agonist medications for weight loss to Medicare and Medicare Advantage beneficiaries at $50 per month. The program covers select brand-name GLP-1 drugs (including Wegovy, Zepbound, and others) but has specific eligibility requirements and limitations. The article explains which medications are included, who qualifies, how the pricing compares to retail costs, and what beneficiaries need to know about the temporary program.
Source
bskyMedicare Launches $50/Month GLP-1 Weight-Loss Drug Trial: What Beneficiaries Need to Knowmedpagetoday.comKey quotes
· 3 pulledStarting this week, the federal government is offering a selection of the brand name medications to certain Medicare and Medicare Advantage beneficiaries for $50 a month through a new trial called Medicare GLP-1 Bridge.
The temporary program, which runs...
Only some of the medications are included
You might also wanna read
CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications
Medicare begins covering weight-loss medications: who qualifies and how the new program will work
:max_bytes(150000):strip_icc()/glp1419-05262026-3b927deb18854c46a35a2eb6f7ccec4a.jpg)
Medicare Will Soon Offer Low-Cost GLP-1 Weight-Loss Drugs. What You Need to Know
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·6mo ago:max_bytes(150000):strip_icc()/GLP1-Now-Affordable-052926-1d50af52042b44b79fc71edef280243d.jpg)
This Mom Saw Success on GLP-1s, but Cost Was 'Becoming Prohibitive.' On July 1, Medicare's $50 Pricing Will Change That
Conflicts of interest threaten integrity of GLP-1 therapy guidance, experts warn
This article discusses the risks of conflicts of interest in clinical guidance for GLP-1 receptor agonists (like Ozempic, Wegovy) used for o
bit.ly·15d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.